The risk of liver cancer may still exist even after liver viruses are cleaned

The latest study completed by researchers from the US Centers for Disease Control and Prevention (CDC) and Anchorage, Alaska Native Tribal Health Association was published in the Journal Digestive Pharmacology and Therapeutics.

Hepatitis B is infected with a liver by the hepatitis B virus (HBV) caused by the human body into another body fluid from an infected person spread occurs in vivo, such as in the sharing of needles and other injection equipment, mother to child transmission at birth. According to CDC, HBV chronic infection the risk of age-related; 90% of children are infected become chronically infected, compared to only 2-6% of adults as chronic.

Since 1991, when the United States launched a national strategic approach to eliminate hepatitis B virus infection, and for the first time recommended routine vaccination of children, emerging in HBV infection has declined by about 82%. CDC estimates that in 2013, the number of newly infected with hepatitis B virus in the United States is 19,764 people, the highest infection rate of adults, especially men aged between 25-44 years. However, the presence of chronic infection very large number of Americans. CDC estimates that in the United States about 700,000-1,400,000 people have chronic HBV infection die of the disease each year is estimated there are about 2,000-4,000 people.

Development of children are chronically infected with approximately 25% of cases, 15% of adult cases of death from cirrhosis or liver cancer, and in most cases, they did not show symptoms until the occurrence of these serious diseases. Worldwide, about 240 million people suffer from chronic hepatitis B, an estimated 786,000 people each year die from hepatitis B-related liver disease.

In their study, the researchers selected subjects were 1,346 cases of patients with chronic HBV infection from Alaska native, they 1982-- followed up in 2013 between. They chose during follow-up of chronic hepatitis B virus infection has been resolved in patients with 238 cases, and 435 are still infected persons (control group) and its match. Patients were matched for age, sex, hepatitis B virus strains aspect. The team found that hepatitis B virus clearance seems to be no significant difference in the risk of developing liver cancer.

The researchers noted that, although we do not know why the clearance of hepatitis B virus does not seem to affect the risk of liver cancer, they think it is probably due to a number of factors. For example, one reason may be in the early stages of infection, hepatitis B virus has been integrated into the genome of liver cells, and can clear the virus persist in the blood traces.

The authors point out in their study that the HBV DNA levels are still detectable in "a significant proportion" of patients with the disease after traces of the virus (anti-viral antibodies) have been cleared from the blood. This increases the possibility of the host "low level of ongoing HBV replication along with the continued integration of" the of liver cells, causing liver cancer risk of the virus from the blood after being cleared still persist. Lead author Prabhu Gounder said, "As adults obviously still have risk of liver cancer after the infection is treated, they may still need close follow-up."

Go through this link: http://www.cusabio.com/ELISA-Kit/Fish-Apolipoprotein-EAPOE-ELISA-kit-1035336.html